Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CTX112 |
Trade Name | |
Synonyms | CTX 112|CTX-112 |
Drug Descriptions |
CTX112 are allogeneic T-lymphocytes engineered to harbor modifications of Regnase-1 and TGFBR2 and express a chimeric antigen receptor (CAR) targeting CD19, which potentially lead to enhanced antitumor immune response and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): ND02). |
DrugClasses | CD19 Immune Cell Therapy 64 |
CAS Registry Number | NA |
NCIT ID | C199293 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CTX112 | CTX112 | 0 | 1 |